Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

stock quote

 

Netscientific PLC
LON:NSCI, £5,25

 

Netscientific PLC
LON:NSCI £5,25

 

LON:NSCI 5 +3 +163%

 

Netscientific PLC NSCI 5,25 +3,25 +162,50%

 

Netscientific PLC NSCI, £5,25

 

NSCI, 5,25, +3,25

 

Netscientific PLC – NSCI, 5,25, +3,25

 

Netscientific PLC NSCI, price £5,25, change +3,25, change percent +162,50%, volume 273523

Netscientific PLC NSCI, NSCI, NSCI, 5,25, +3,25, +162,50%, 273523

stock quote - NetScientific